Description: Horizon Pharma, Inc., a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The company offers DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. It also provides LODOTRA/RAYOS, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active rheumatoid arthritis in adults when accompanied by morning stiffness, as well as approved for the treatment of polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, and other conditions. The company was founded in 2005 and is headquartered in Deerfield, Illinois.
Home Page: www.horizontherapeutics.com
HZNP Technical Analysis
70 St. Stephen’s Green
Dublin,
2
Ireland
Phone:
353 1 772 2100
Officers
| Name | Title |
|---|---|
| Mr. Timothy P. Walbert | Chairman, Pres & CEO |
| Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. | Exec. VP & Chief Medical Officer |
| Mr. Paul W. Hoelscher | Advisor |
| Mr. Andy Pasternak | Exec. VP & Chief Strategy Officer |
| Mr. Aaron L. Cox | Exec. VP of Fin. & CFO |
| Mr. Patrick McIlvenny | Sr. VP & Chief Accounting Officer |
| Ms. Tina E. Ventura | Sr. VP & Chief Investor Relations Officer |
| Mr. Sean M. Clayton J.D. | Exec. VP & Gen. Counsel |
| Mr. Geoffrey M. Curtis | Exec. VP of Corp. Affairs & Chief Communications Officer |
| Ms. Jane Gonnerman | Sr. VP of Corp. Devel. & Chief of Staff, Office of the CEO |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 21.7391 |
|---|---|
| Trailing PE: | 46.5473 |
| Price-to-Book MRQ: | 5.1009 |
| Price-to-Sales TTM: | 6.9288 |
| IPO Date: | 2011-07-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 2095 |